FDA Says J&J Vaccine Meets Requirements For Emergency Use Authorization

What Happened:

• On Wednesday, the FDA announced that the Johnson & Johnson Covid-19 vaccine has met the requirements necessary for emergency use authorization. If approved, it would be the first single-dose vaccine authorized to treat the virus.

• The Johnson & Johnson vaccine was found to be 66.9% effective at preventing moderate to severe Covid-19 symptoms and 85% effective against very serious symptoms. The J&J vaccine was less effective against the mutated South African version of the virus.

• The FDA analysis says "there were no specific safety concerns identified in subgroup analyses by age, race, ethnicity, medical comorbidities, or prior SARS-CoV-2 infection" with the J&J vaccine.

• The FDA committee will meet on Friday to make the final determination if the J&J vaccine receives emergency use approval.

• J&J says they can roll-out 100 million doses by the end of June, if they receive FDA approval.

• Although less effective than the two-dose Pfizer and Moderna vaccines, J&J's single-dose vaccine could be much easier to roll-out and does not require the same sub-zero refrigeration, facilitating transportation and storage.

Photo Source: Pixabay

#newspura #justfactsnoopinions #covid19 #coronavirus #vaccine #johnsonandjohnson #oneshotvaccine #news #breaking #breakingnews #emergencyuseauthorization